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Abstract
Background: Quality control results for serum MUC-
1/CA 15-3 assays have always shown large discrep-
ancies.
Methods: This multicentre study of 15 methods
(labelled M1-M15) measured coded sera from 35
patients with breast cancer without recurrence (group
1), 46 patients at 1st metastasis (group 2), and 39
patients with advanced metastases (group 3). Results
were compared using parametric statistics, ANOVA,
principal component analysis, and receiver operating
characteristic (ROC) curves.
Results: Mean MUC-1/CA 15-3 concentrations varied
widely (75.1–303.0 U/mL, 24.8%) among methods.
The false positive (FP) rate for group 1 was 8/521
(1.5%); for group 2 and group 3 false negative (FN)
results were 21/680 (3.1%) and 11/583 (1.9%), respec-
tively. Using the ROC cut-offs, we found no FPs for
group 1 and no FNs for group 3. However, group 2
showed 16 FNs. All p-values for Pearson’s correlation
were -0.0001 between methods, except for M11.
When comparing methods using different antibodies,
discordance rates reached a maximum of 15.2%. Prin-
cipal component analysis revealed a grouping of
methods using: CanAg monoclonal antibodies (mAbs)
(M2, M7 and M12); Centocor/Fujirebio mAbs (M3-M6,
M8-M10, M14-M15) and Biomira mAbs (M1 and M13);
and Centocor/Fujirebio mAbs (M11).
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Conclusions: Results were more consistent among
methods using the same antibody type. Principal
component analysis showed that antibody type was
the strongest determinant of immunoassay results.
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Introduction
Tumour marker cancer antigen (CA) 15-3 and its ana-
logues, defined as MUC-1/CA 15-3, correspond to an
immunodominant epitope of the protein core of the
membrane MUC-1 mucin, a highly heterogeneous
molecule. Located in the extracellular domain of the
MUC-1 mucin, this epitope resides within a hydro-
philic region of seven amino acids (PDTRPAP) belong-
ing to the 20 amino acids tandem repeat sequences.
MUC-1 mucin is overexpressed in carcinomas (1, 2).
Increased concentrations of MUC-1/CA 15-3 are found
in metastatic breast cancer and serial assays of this
marker are used to monitor tumour response during
treatment (3).
The CA 15-3 tumour marker is not a clearly defined
analyte. The original CA 15-3 assay is defined by two
monoclonal antibodies (mAbs): 115 D8, developed
against milk fat globule, and DF3, developed against
membranes of human breast cancer cells (Centocor/
Fujirebio). The DF3 mAb recognises the epitope
APDTRPAP, a sequence that contains the common
DTR motif recognised by more than 20 different anti-
MUC-1 antibodies (4–8). These two mAbs are com-
ponents of several MUC-1/CA 15-3 immunoassay
formats used in clinical settings. Other mAbs that
recognise amino acid sequences spanning the DTR
motif, such as B27.29 (PDTRPAP) (Biomira) or Ma 552
(PDTRPAPG) (CanAg), are also used for measurement
of MUC-1/CA 15-3 in breast cancer (9).
Method comparison studies and inter-laboratory
quality control for serum MUC-1/CA 15-3 assays have
always shown large discrepancies among results
(10–12). For that reason, the French Health Products
Agency, Agence Francaise de Se´curite´ Sanitaire des¸
Produits de Sante´ (AFSSAPS) launched a multicentre
evaluation of 15 methods marketed in France for the
measurement of CA 15-3 or of CA 15-3 analogs, CA
27.29, BR, or BR-MA (CA 15-3). To facilitate compari-
sons among methods, all 12 participating laboratories
tested the same serum samples. Results of the
AFSSAPS evaluation showing the clinical sensitivity
and specificity of the different methods have been
published (13). The present work focuses on the sta-
tistical analysis of the AFSSAPS panel data, in order
to help define the origin of discrepancies in MUC-1/
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CA 15-3 concentrations when using different methods
on the same samples.
Patients and methods
Patients and sera
For serum MUC-1/CA 15-3 assays, there is no primary ref-
erence material for calibration or a reference method for
comparison. Therefore, we used the clinical status of a panel
of breast cancer patients to compare the performance of the
different methods in terms of clinically adequate MUC-1/CA
15-3 results. We established a protocol that defined three
patient groups. We excluded, as best as possible, risks of
both false negative (FN) MUC-1/CA 15-3 results and non-spe-
cific increases in MUC-1/CA 15-3. The selection of sera to be
included in the panel and distributed to participating labo-
ratories was based on strictly defined clinical criteria
approved by three expert oncologists.
At the time of blood sampling, clinical status of patients
was evaluated by oncological examination and medical
imaging, pathology, and laboratory tests, according to the
Standards Options and Recommendations of the French
Fe´de´ration des Centres de Lutte Contre le Cancer (14). All
cancer related events during patient follow up had to be doc-
umented by at least one imaging technique (X-rays, CT-scan,
echography, PET-scan) or by puncture cytology, biopsies, or
pathologic examination following surgical removal.
Group 1, comprised of breast cancer patients undergoing
active follow-up following primary treatment, showed no
recurrence during an observation period of at least 4 years
after initial diagnosis. Group 2 consisted of patients at their
first metastasis, with blood collection performed between 0
and 90 days before proven metastasis in order to take into
account an eventual lead time phenomenon. Group 3
patients were all known to have metastases, with blood col-
lection performed at least 90 days after the diagnosis of
metastases. Five exclusion rules, based on case types, were
strictly followed: all cases with oestrogen receptor-negative
tumours, since the MUC-1 gene is regulated by oestrogens;
cases with increased MUC-1/CA 15-3 without any proven
recurrence; cases with proven recurrence without increases
in MUC-1/CA 15-3; cases with isolated local recurrences or
recurrences preceding a first metastasis; and cases with pre-
vious or associated second cancer. Additional exclusion cri-
teria were defined as: pregnancy, associated breast benign
pathologies, associated inflammatory, infectious or auto-
immune diseases, patients with significant metabolic
alterations.
Frozen (F–208C) serum samples were retrieved from
blood banks (MFP, JPB, NE, and JMR), or obtained from
patients at their respective Cancer Centres. A minimum of
2 mL of serum was required for analysis by all methods.
Initial CA 15-3 concentration was measured by immuno-
radiometric assay (ELSA CA 15-3, Cis Bio International, Gif
sur Yvette, France, MFP) or by immunofluorometric assay
(Kryptor, Brahms, Clichy, France, JPB, NE, JMR). This study
was performed in accordance with the Declaration of Helsin-
ki Ethical Guidelines.
Methods evaluated
This study tested 15 assay methods, both manual and auto-
mated, available in the French market in 2005: Architect CA
15-3 and Axsym CA 15-3 (Abbott Diagnostic, Rungis, France),
CA 15-3 Kryptor (Brahms, Clichy, France), Advia Centaur CA
15-3 and Advia Centaur BR CA 15-3 (Bayer Diagnostics,
Puteaux, France), Access BR monitor (Beckman Coulter,
Villepinte, France), Vidas CA 15-3 (Biomerieux, Marcy
l’Etoile, France), ELSA CA 15-3 (Cis Bio International, Gif sur
Yvette, France), Liaison CA 15-3 and CA 15-3 IRMA (DIA
Sorin, Antony, France), Immulite 2000/2500 BR-MA (DPC, La
Garenne-Colombes, France), IRMA MUC-1 CA 15-3 (Immu-
notech, Marseille, France), Vitros CA 15-3 (Ortho Clinical
Diagnostics, Issy-les Moulineaux, France), Elecsys CA 15-3 II
(Roche Diagnosis, Meylan, France), and AIA Pack 27.29,
(Tosoh Bioscience, Saran, France). When identical assay
methods were available for use with different immunoassay
systems, only the most popular was evaluated. Immunora-
diometric assays, Bayer Advia Centaur, and Brahms Kryptor
methods were evaluated in AFSSAPS laboratories (MFP,
JPB, JMR, NE, YF). For the other methods, the choice of the
laboratories in charge of the assays was made in concert
with the manufacturers. All biologists had to follow manu-
facturer’s recommendations exactly. Serum samples were
coded before being sent to the participating laboratories for
double blind assays to eliminate any indication of patient
groups.
Statistical methods
Our statistical comparisons of methods did not involve the
use of any particular method as a reference method. MUC-
1/CA 15-3 concentrations were analysed as continuous or
dichotomised (normal/increased) variables, according to the
cut-off values given by each manufacturer. For the transfor-
mation of concentrations close to cut-off levels into binary
variables, we considered non-significant differences to be
those values within 5% of the cut-off level.
All statistical analyses were performed using SAS Statis-
tical Software packages (version 8.2, SAS Institute, Cary, NC,
USA). Descriptive statistics have been computed for all the
measurements in the overall group, as well as in the three
defined patient subgroups. Relationships between different
methods were analysed using a parametric test, with deter-
mination of Pearson’s correlation coefficient. Agreement
between methods was calculated using the intraclass cor-
relation coefficient (ICC). A multivariate variance analysis
(MANOVA) was performed in order to assess the group
effect taking into account all methods. Factor analysis began
with a matrix of intercorrelations among all methods used
in the evaluation. The goal of factor analysis is to determine
a smaller number of factors that help explain these correla-
tions. Prior to submitting data for analysis, they were
inspected for meeting the assumptions of factor analysis.
The suitability assessment of the correlation matrix for factor
analysis involved the computation of the Kaiser-Meyer-Olkin
index, the Bartlett’s test of sphericity and the examination of
the anti-image covariance matrix. Once the correlation
matrix has been determined as suitable for factor analysis,
the chosen method for factor extraction was the principal
components analysis (PCA) with the Varimax rotation for
improving interpretability of retained factors. These retained
factors have been determined by the Scree test as well as
by the Kaiser rule.
Receiver operating characteristic analysis (ROC) was per-
formed using MedCalc statistical software (v. 9.3, Maria-
kerke, Belgium).
Results
Sera from 35 patients in group 1, 46 patients in group
2, and 39 patients in group 3 fulfilled the requirements
for inclusion in the panel to be analysed. The mean
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Table 1 All patients. Distribution of MUC-1/CA 15-3 concentrations (U/mL) according to the different methods.
Method mAb n Mean SD Median Minimum Maximum 1st quartile 3rd quartile
M1 Biomira 113 92.4 92.6 58.7 6.2 395.0 24.6 125.5
M13 Biomira 119 303.0 1683.5 81.1 4.0 18,315.2 24.3 190.4
M2 CanAg 119 176.1 281.7 90.0 8.0 1719.0 32.0 184.0
M7 CanAg 118 165.8 859.0 42.2 4.0 9301.0 18.3 88.4
M12 CanAg 103 75.2 60.1 63.1 7.9 247.0 20.7 118.4
M3 Cen/Fuji 120 276.5 1734.3 54.4 4.4 18,983.0 21.1 145.4
M4 Cen/Fuji 118 129.3 186.3 56.0 5.6 1025.0 23.3 162.7
M5 Cen/Fuji 120 202.8 911.2 61.0 6.0 9827.0 20.5 144.0
M6 Cen/Fuji 114 98.5 115.0 55.4 5.3 628.0 21.4 139.3
M8 Cen/Fuji 111 75.1 75.1 45.1 5.4 337.0 19.3 117.1
M9 Cen/Fuji 111 110.2 114.5 66.3 6.6 488.0 24.8 159.0
M10 Cen/Fuji 104 64.3 59.0 41.6 7.3 240.1 18.5 91.1
M11 Cen/Fuji 107 60.7 57.6 39.7 2.6 275.8 18.6 86.1
M14 Cen/Fuji 120 229.2 1210.5 54.0 2.7 13,183.6 20.6 147.0
M15 Cen/Fuji 120 265.2 1454.0 63.7 4.9 15,839.2 22.9 143.6
mAb, monoclonal antibodies; Cen/Fuji, Centocor/Fujirebio.
age of patients was 54.9"12.8 years, and 72.8% were
menopausal. Methods were randomly labelled
M1–M15. One hundred and twenty serum samples
were assayed using 15 methods; 10 using Centocor/
Fujirebio mAbs (M3-6, M8-11, M14-15), 3 using CanAg
mAbs (M2, 7, 12) and 2 using B 27.29 (Biomira) mAbs
(M1 et M13). Results from method M8 were asked to
be withdrawn by the manufacturer because of possi-
ble underestimation with the current reagent. How-
ever, since no significant difference was found
between these results and those obtained with the
other methods, we decided to keep results from M8
in the statistical analyses.
A total of 1792 MUC-1/CA 15-3 results were
obtained. Eight were missing because of insufficient
serum volume for some assays. One thousand seven
hundred and sixteen results were reported as contin-
uous variables and were dichotomised; 76 results
were used as dichotomous variables since six were
below the detection limits of the assay; and 70 were
greater than the highest concentration used for the
standard curve, and with insufficient serum volume
for reanalysis.
Stability of CA 15-3 in deep frozen serum samples
We verified that CA 15-3 concentrations were not
altered after the process of thawing, aliquoting and
refreezing required to provide samples to all partici-
pating laboratories. Forty-eight blood bank sera, ini-
tially assayed by ELSA CA 15-3, were further tested
in a different laboratory using the same method.
Results correlated well: the regression line obtained
was y (2nd assay)s–0.1394q0.9756=(1st assay),
p-0.0001, with mean"SD CA 15-3 concentrations of
51.8"47.8 U/mL at 1st assay vs. 50.4"47.2 U/mL after
retesting (non-significant difference). The same com-
parison was done for the Kryptor technique and a
good correlation was also observed: regression equa-
tion was y (2nd assay)s1.8234q0.9311=(1st assay),
p-0.0001, with mean"SD initial CA 15-3 of 108.1"
91.8 U/mL vs. 102.4"87.5 U/mL after dispatching
(ns62, non-significant difference). Thus, despite a
slight decrease after producing aliquots for analysis,
we considered that MUC-1/CA 15-3 was not signifi-
cantly affected by freezing and thawing.
Descriptive statistics
Tables 1–4 show the distribution of MUC-1/CA 15-3
concentrations according to the different methods
and patient groups. Depending on the method, mean
MUC-1/CA 15-3 concentrations vary considerably
(75.1–303.0 U/mL, 24.8%, Table 1). For each method,
a variance analysis of the MUC-1/CA 15-3 results by
patient groups showed a significant difference in all
cases (p-0.0001), thus validating the choice of serum
for each group.
Variation between different methods (and different
antibodies) was more obvious in sera from patients
with recurrence compared to patients from group 1
who were expected to have low MUC-1/CA 15-3 con-
centrations. In group 1, two methods (M1, ns7, M4,
ns1) gave false positive (FP) (increased) results, cor-
responding to an overall FP rate of 8/521 (1.5%). For
group 2, six methods (M3, ns2, M7, ns6, M8, ns3,
M10, ns2, M11, ns6, M14, ns2) gave FN (normal)
results, with a total of 21/680 (3.1%) FN results. Group
3 showed 11/583 (1.9%) FN results: M1, M2, M3, M12,
M13 and M14 methods each showed 1 FN result, M7
and M8 methods 3 and 2 FN results, respectively.
Correlations
Within the overall patient group, and between meth-
ods taken two by two, all p-values for Pearson’s cor-
relation coefficients were -0.0001, except for method
M11. For the latter, all Pearson’s correlation coeffi-
cients were -0.60 (non-significant) with regard to
methods M3 (ns107, ps0.1962), M5 (ns107, ps
0.0968), M7 (ns105, ps0.1565), M13 (ns107,
ps0.1520), M14 (ns107, ps0.1484) and M15 (ns107,
ps0.1556). When calculating pairwise ICCs by
ANOVA to evaluate homogeneity between results
obtained by the different methods, results from group
1 patients were found to be more homogeneous than
those from other groups (Table 5). ICC results
grouped by antibody type showed different levels of
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Table 2 Group 1 (patients without recurrence). Distribution of MUC-1/CA 15-3 concentrations (U/mL) according to the differ-
ent methods.
Method mAb n Mean SD Median Minimum Maximum 1st quartile 3rd quartile
M1 Biomira 35 16.2 7.1 14.8 6.2 30.9 10.0 22.2
M13 Biomira 34 14.7 7.2 13.3 4.0 30.2 9.6 19.9
M2 CanAg 35 20.9 9.0 18.0 8.0 39.0 13.0 28.0
M7 CanAg 33 12.0 6.0 9.9 4.0 25.6 7.3 15.2
M12 CanAg 35 17.1 6.2 16.1 7.9 34.3 10.1 16.1
M3 Cen/Fuji 35 13.5 5.7 12.6 4.4 24.7 8.7 19.3
M4 Cen/Fuji 35 15.5 6.3 14.0 5.6 28.9 9.4 21.6
M5 Cen/Fuji 35 14.0 4.9 13.0 6.0 23.0 10.0 18.0
M6 Cen/Fuji 35 15.4 5.8 14.8 5.3 25.1 10.8 21.0
M8 Cen/Fuji 35 13.6 5.9 13.1 5.4 24.7 7.7 18.0
M9 Cen/Fuji 35 17.6 7.6 15.5 6.6 31.5 11.0 24.7
M10 Cen/Fuji 35 14.3 4.7 14.0 7.3 25.0 9.9 18.8
M11 Cen/Fuji 31 12.8 6.4 11.9 2.6 24.9 7.4 18.0
M14 Cen/Fuji 35 12.2 6.1 10.5 2.7 22.9 8.2 17.8
M15 Cen/Fuji 35 14.5 6.1 12.7 4.9 26.9 9.4 19.7
mAb, monoclonal antibodies; Cen/Fuji, Centocor/Fujirebio.
Table 3 Group 2 (patients at first metastasis). Distribution of MUC-1/CA 15-3 concentrations (U/mL) according to the different
methods.
Method mAb n Mean SD Median Minimum Maximum 1st quartile 3rd quartile
M1 Biomira 44 88.0 68.2 71.7 28.8 382.2 50.2 92.9
M13 Biomira 46 512.6 2686.0 81.5 46.1 18,315.2 60.8 106.7
M2 CanAg 45 170.5 280.1 98.0 46.0 1719.0 63.0 134.0
M7 CanAg 46 284.8 1365.7 46.9 19.3 9301.0 34.3 72.3
M12 CanAg 42 85.2 43.0 73.2 40.5 238.7 55.1 93.2
M3 Cen/Fuji 46 487.9 2788.3 55.4 28.3 18,983.0 42.1 87.6
M4 Cen/Fuji 45 90.3 92.1 58.3 24.6 461.0 43.5 97.8
M5 Cen/Fuji 46 298.4 1438.7 61.0 30.0 9827.0 44.0 88.0
M6 Cen/Fuji 44 81.9 66.0 57.8 29.8 332.8 48.2 83.1
M8 Cen/Fuji 43 68.4 54.9 52.6 21.3 337.0 39.5 76.5
M9 Cen/Fuji 43 105.5 94.7 75.3 33.5 456.0 57.4 108.0
M10 Cen/Fuji 43 63.2 36.6 53.9 22.6 185.1 38.0 84.0
M11 Cen/Fuji 46 59.7 46.9 40.9 13.0 252.6 32.7 65.2
M14 Cen/Fuji 46 363.4 1933.3 55.2 22.8 13,183.6 40.6 94.3
M15 Cen/Fuji 46 430.2 2324.2 63.9 36.3 15,839.2 46.9 83.6
mAb, monoclonal antibodies; Cen/Fuji, Centocor/Fujirebio.
Table 4 Group 3 (patients with metastasis). Distribution of MUC-1/CA 15-3 concentrations (U/mL) according to the different
methods.
Method mAb n Mean SD Median Minimum Maximum 1st quartile 3rd quartile
M1 Biomira 34 176.6 97.5 155.9 32.90 395.0 114.5 215.8
M13 Biomira 39 307.1 359.1 209.6 35.30 2140.3 147.3 338.8
M2 CanAg 39 321.7 333.8 198.0 32.00 1586.0 126.0 388.0
M7 CanAg 39 155.7 159.7 88.4 18.10 673.9 62.3 215.8
M12 CanAg 26 137.3 52.5 144.2 30.90 247.0 99.7 165.0
M3 Cen/Fuji 39 263.3 308.5 166.3 28.20 1676.0 110.2 265.7
M4 Cen/Fuji 38 280.3 249.2 193.1 38.53 1025.0 127.7 352.1
M5 Cen/Fuji 39 259.9 319.2 152.0 29.00 1911.0 125.0 275.0
M6 Cen/Fuji 35 202.6 140.7 169.0 31.10 628.0 103.8 169.0
M8 Cen/Fuji 33 149.1 74.4 135.2 19.54 320.1 107.7 178.6
M9 Cen/Fuji 33 214.7 112.1 207.0 41.60 488.0 138.0 266.0
M10 Cen/Fuji 26 133.5 60.1 130.6 33.10 240.1 93.7 179.1
M11 Cen/Fuji 30 111.6 59.6 106.2 30.40 275.8 64.9 149.0
M14 Cen/Fuji 39 265.8 310.0 170.0 28.30 1691.6 122.5 253.0
M15 Cen/Fuji 39 295.7 363.0 165.7 31.70 1898.5 127.1 296.9
mAb, monoclonal antibodies; Cen/Fuji, Centocor/Fujirebio.
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Table 6 Pairwise intraclass correlation coefficient (ICC) according to the type of antibody (ANOVA).
Antidody Method Group ICCF0.40 0.40-ICCF0.75 0.75-ICCF0.90 ICC)0.90
Biomira M1, M13 1 0 0 0 1 (100%)
(CA 27.29) 2 0 0 1 (100%) 0
3 0 0 1 (100%) 0
All patients 0 0 1 (100%) 0
CanAg M2, M7, M12 1 0 2 (67%) 1 (33%) 0
2 0 3 (100%) 0 0
3 1 (33%) 2 (67%) 0 0
All patients 0 2 (67%) 1 (33%) 0
Centocor/ M3–M6, 1 0 (0%) 8 (18%) 15 (33%) 22 (49%)
Fujirebio M8–M11, 2 4 (9%) 9 (20%) 23 (51%) 9 (20%)
M14, M15 3 1 (2%) 15 (33%) 17 (38%) 12 (27%)
All patients 4 (9%) 2 (4%) 16 (36%) 23 (51%)
Group 1, patients without recurrance; group 2, patients at their 1st metastasis; group 3, patients with advanced metastasis.
Table 5 Results of ANOVA: pairwise intraclass correlation coefficient (ICC).
ICC Group 1 Group 2 Group 3 All patients
ICCF0.40 1 (1%) 15 (14%) 11 (10%) 8 (8%)
0.40-ICCF0.75 32 (30%) 37 (35%) 44 (42%) 18 (17%)
0.75-ICCF0.90 41 (39%) 38 (36%) 31 (30%) 44 (42%)
ICC)0.90 31 (30%) 15 (14%) 19 (18%) 35 (33%)
Total ICCG0.75 72 (69%) 53 (50%) 50 (48%) 79 (75%)
homogeneity: with B 27.29 (Biomira, 2 methods), all
ICCs were )0.75, for CanAg antibodies (3 methods),
the majority of ICCs were between 0.40 and 0.75 and
with Centocor/Fujirebio antibodies (10 methods), the
majority of ICCs was )0.75 (Table 6).
Analysis of discordances between methods
In this analysis, MUC-1/CA 15-3 concentrations were
analysed as binary variables. Table 7 shows the per-
cent discordance by methods taken two by two in the
overall patient group. Maximum discordance was
7.5% for methods using Biomira (CA 27.29) mAbs,
8.5% for CanAg mAbs and 5.9% for Centocor/Fujirebio
mAbs. When comparing methods using different anti-
bodies, discordance rates were found to be greater
(up to 15.2%).
Manufacturers’ calculations for cut-off values were
heterogeneous and consequently could impact clas-
sification of patients. To verify if the cut-off values
provided by the manufacturers were optimised, we
performed ROC curve analysis using group 1 patients
as non-recurring and groups 2 and 3 as patients with
recurrence. For two methods only, the cut-off values
obtained using ROC analysis differed by -10% from
the one given in the manufacturer’s instructions
(Table 8). When using the ROC cut-offs to calculate
the sensitivity and specificity of each method, no FP
results for group 1 patients and no FN results for
group 3 patients were obtained. For patients in group
2, 16 FN results were obtained (ns1 for methods M1,
M2, M4, M10 and M12, ns3 for M8, and ns4 for M7
and M11).
Principal component analysis
To explore the interrelationships among methods, all
15 methods were subjected to PCA for the total group.
Prior to performing PCA, the suitability of the data for
factor analysis was assessed. Inspection of the cor-
relation matrix revealed the presence of many coef-
ficients above 0.3. The Kaiser-Meyer-Olkin index was
0.92, exceeding the recommended value of 0.6 and
Barlett’s test of sphericity reached statistical signifi-
cance (p-0.00001), supporting factoring of the cor-
relation matrix. The Kaiser rule (eigenvalues )1) and
the Scree plot of eigenvalues showed that the 15
variables corresponding to the methods could be
reduced to two factors, explaining 96.4% of the vari-
ance in the overall patient group. Final results after
Varimax rotation are shown in Figure 1, where the
influence of the antibody type is indicated by the visu-
al grouping of methods. Three groups of methods can
be discerned: M2, M7 and M12 using CanAg antibod-
ies, a large group including M1 and M13 (Biomira
mAbs) together with M3-M6, M8-M10, M14-M15 (Cen-
tocor/Fujirebio mAbs), and M11, using Centocor/Fuji-
rebio mAbs, was isolated in a third group. Among
IRMA assays (M10, M11 and M12), M12 using CanAg
mAbs is in the area of the other methods using CanAg
mAbs, but not in the Centocor/Fujirebio mAbs groups.
Discussion
Most molecules used as tumour markers are derived
from complex glycoproteins. Serum markers such as
MUC-1/CA 15-3 have an abnormal structure in cancer
cells, and their molecular structures vary according to
tumour type (15). With the exception of a-fetoprotein,
human choriogonadotrophin, and prostate specific
antigen, such molecular complexity has hampered
the preparation of reference material and the devel-
opment of an internationally accepted reference
method (16, 17). This may help explain the challenge
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Table 7 All patients. Proportion of discordant binary results by methods.
M1* M13* M2** M7** M12** M3 M4 M5 M6 M8 M9 M10 M11 M14 M15
M1* 0.0000 0.0750 0.0667 0.1525 0.0667 0.0833 0.0583 0.0750 0.0678 0.1176 0.0678 0.0833 0.1083 0.0833 0.0583
M13* 0.0000 0.0083 0.0763 0.0083 0.0250 0.0333 0.0167 0.0254 0.0059 0.0254 0.0417 0.0667 0.0250 0.0167
M2** 0.0000 0.0847 0.0167 0.0333 0.0417 0.0250 0.0339 0.0672 0.0339 0.0500 0.0750 0.0333 0.0250
M7** 0.0000 0.0847 0.0847 0.1102 0.0932 0.0862 0.0940 0.1034 0.1186 0.1271 0.0847 0.0932
M12** 0.0000 0.0167 0.0250 0.0083 0.0169 0.0050 0.0169 0.0333 0.0583 0.0167 0.0083
M3 0.0000 0.0417 0.0250 0.0169 0.0336 0.0169 0.0333 0.0333 0.0000 0.0250
M4 0.0000 0.0167 0.0254 0.0588 0.0254 0.0250 0.0500 0.0417 0.0167
M5 0.0000 0.0254 0.0420 0.0254 0.0250 0.0500 0.0250 0.0167
M6 0.0000 0.0513 0.0172 0.0339 0.0424 0.0169 0.0085
M8 0.0000 0.0051 0.0336 0.0420 0.0336 0.0059
M9 0.0000 0.0169 0.0424 0.0169 0.0085
M10 0.0000 0.0417 0.0333 0.0250
M11 0.0000 0.0417 0.0500
M14 0.0000 0.0250
M15 0.0000
*Biomira mAbs; **CanAg mAbs; all other methods use Centocor/Fujirebio mAbs. In bold: discordance rates )maximum percent
discordance observed in method comparison using similar antibodies; in italic: comparison of methods using different mAbs.
Table 8 Results of ROC curve analysis for the different methods.
Methods Manufacturer n n AUC Optimal Se, %* Sp, %*
cut-off value, ‘‘without ‘‘with cut-off
U/mL recurrence’’ recurrence’’ value,
U/mL
M1 23.4 78 35 0.999 30.9 98.7 100.0
M2 38 84 35 0.998 39.0 97.6 100.0
M3 31.3 85 35 1.000 24.7 100.0 100.0
M4 25 83 35 1.000 28.9 98.8 100.0
M5 30 85 35 1.000 23.0 100.0 100.0
M6 30 79 35 1.000 25.1 100.0 100.0
M7 31.3 84 33 0.994 25.6 95.2 100.0
M8 30 76 35 0.994 24.7 96.1 100.0
M9 35 76 35 1.000 31.5 100.0 100.0
M10 30 69 35 0.999 25.0 97.1 100.0
M11 28 76 31 0.986 24.9 93.4 100.0
M12 35 68 35 1.000 34.3 98.5 100.0
M13 38.6 85 34 1.000 30.2 100.0 100.0
M14 32.4 85 35 1.000 22.9 98.8 100.0
M15 31.3 85 35 1.000 26.9 100.0 100.0
AUC, area under ROC curve; Se, clinical sensitivity; Sp, clinical specificity; *values are overestimated since patients were not
taken at random.
of standardizing tumour marker assays. Consequent-
ly, tumour marker results are known to be strongly
dependent on the assay method, a concern that has
complicated their acceptance for clinical use (18).
In the present work, we did not attempt to compare
the analytical performance among different methods,
as our focus was on evaluating the clinical relevance
of the results. We chose to use individual patient sera
only, and thus avoid bias due to artificial quality con-
trol preparations (19). In addition, all serum samples
were tested by all 15 methods.
Taking AFSSAPS panel results as a whole, we
found the rates of FP (elevated MUC-1/CA 15-3 in non-
recurring breast cancer patients), or FN (MUC-1/CA
15-3 results under cut-off in metastatic patients) to be
consistent with those observed among classical bio-
logical parameters. A major conclusion of our work is
that a uniform calculation by ROC curve analysis of
the results obtained with patient groups of adequate
size significantly reduces these discrepancies (20). As
expected, sera from group 2 patients (recent first
metastasis and moderate increases in MUC-1/CA 15-3),
showed the highest (3.1%) rate of FN results, depend-
ing on the analytical sensitivity of the techniques.
Sera from this type of patient should be carefully
studied by manufacturers to optimise the clinical sen-
sitivity of the assay to enable early detection of
metastases.
In the whole panel of sera, we observed consider-
able variations in the range of MUC-1/CA 15-3 con-
centrations. They varied from 395 U/mL to 18,315 U/mL
for methods using Biomira Mabs, 247–930 U/mL for
methods based on CanAg Mabs and from 275 U/mL
to 18,983 U/mL for methods using Centocor/Fujirebio
Mabs. This suggests that at least some methods are
prone to hook effects in the presence of elevated
MUC-1/CA 15-3, as was evidenced by three of us (JPB,
NE and JMR) with the Kryptor method.
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Figure 1 Results of principal component analysis.
After Varimax rotation, methods are grouped according to
their relative weight on the first and second component. M2,
M7 and M12sCanAg antibodies, M1 and M13sCA 27.29
(Biomira) mAbs, M3–M6, M8–M10, M11, M14–M15s
Centocor/Fujirebio mAbs.
Discordance rates were low and homogenous
among methods based on the same antibody type,
but higher when comparing methods using different
antibodies. This finding is illustrated by principal
component analysis that grouped together methods
based on Centocor/Fujirebio and Biomira mAbs. Epi-
topes recognised by DF3 mAb and antibodies against
CA 27.29 (Biomira) differ by one amino acid only at
their N-terminal side; the CA 27.29 being devoid of the
Ala residue. Methods using CanAg Ma 552 antibody,
which were displayed separately, recognise an epi-
tope identical to the Biomira mAb, but with a Gly res-
idue added on its C-terminal side. This probably
results in a difference in the secondary structure of
the Ma 552 epitope, slightly changing the specificity
of that antibody.
Overall, this study highlights the pivotal importance
of antibody type in the performance of MUC-1/CA
15-3 immunoassays: principal component analysis
showed that it was the strongest determinant of assay
results, weighing more than the immunoassay sys-
tem used, the method category, or the type of end-
point signal measured.
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